KMT2A and neoplasm: Fidaxomicin treatment of MLL-rearranged HSC cells inhibited cell growth in vitro and reduced tumor burden when combined with doxorubicin in an NSG xenograft model transplanted with HSC-derived MLL-AF6 cells (Zeisig et al., 2021).